Aidoc has raised $150 million in a Series E funding round, bringing total investment in the clinical AI company to more than $500 million.
The new capital will support further development of Aidoc's CARE (Clinical AI Reasoning Engine) foundation model, expansion into additional clinical indications, and new capabilities such as automated imaging draft report creation, Aidoc said. It will also drive broader global deployment of its aiOS enterprise AI platform, the firm noted.
The round was led by Growth Equity at Goldman Sachs Alternatives, with participation from General Catalyst, SoftBank Investment Advisors, and NVentures, NVIDIA's venture capital arm, the company said.
Aidoc noted that its technology analyzes more than 60 million patient cases annually and is deployed across nearly 2,000 hospitals worldwide.













![A normal mammogram confirmed by three-year radiologic follow-up illustrates reader-marked regions of interest (ROIs) during (A) unaided (round 1) and (B) artificial intelligence (AI)–assisted (round 2) reading. Each colored dot represents an ROI for recall by a human reader. Readers could mark more than one ROI per case, represented by multiple dots of the same color. During AI-assisted reading, the AI system displayed three visible prompts: two with suspicion of malignancy scores of 35% (left mediolateral oblique [L MLO] and craniocaudal [L CC]) and one with a suspicion of malignancy score of 10% (right craniocaudal [R CC]), shown as polygonal overlays. Without AI, six of 10 readers (60%) marked a false-positive ROI. With AI assistance, this fell to two of 10 (20%). R MLO = right mediolateral oblique.](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/07/2026-07-14-radiology-mammogram-ai-auto-bias.H0bYO8QlWs.jpg?auto=format%2Ccompress&fit=crop&h=112&q=70&w=112)





